Treatment Optimization of Maintenance Immunosuppressive Agents in Pediatric Renal Transplant Recipients

Publication: Expert Opin Drug Metab Toxicol
Division: Cognigen


Graft survival in pediatric kidney transplant patients has increased significantly within the last three decades, correlating with the discovery and utilization of new immunosuppressants as well as improvements in patient care. Despite these developments in graft survival for patients, there is still improvement needed, particularly in long-term care in pediatric patients receiving grafts from deceased donor patients. Maintenance immunosuppressive therapies have narrow therapeutic indices and are associated with high inter-individual and intra-individual variability. Areas covered: In this review, we examine the impact of pharmacokinetic variability on renal transplantation and its association with age, genetic polymorphisms, drug-drug interactions, drug-disease interactions, renal insufficiency, route of administration, and branded versus generic drug formulation. Pharmacodynamics are outlined in terms of the mechanism of action for each immunosuppressant, potential adverse effects, and the utility of pharmacodynamic biomarkers. Expert opinion: Acquiring a better quantitative understanding of immunosuppressant pharmacokinetics and pharmacodynamic components should help clinicians implement treatment regimens to maintain the balance between therapeutic efficacy and drug-related toxicity.

By, Kathleen M Job, Jessica K Roberts, Elena Y Enioutina, Sílvia M IIIamola, Shaun S Kumar, Jahidur Rashid, Robert M Ward, Tsuyoshi Fukuda, Joseph Sherbotie, Catherine M Sherwin